Therapeutic Hotline: Letter
Complete healing of basal cell carcinoma under bendamustine and brentuximab vedotin therapy in a patient with cutaneous lymphoma
Can Baykal,
Can Baykal
Department of Dermatology and Venereology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Search for more papers by this author Armagan Kutlay,
Corresponding Author
Armagan Kutlay
Department of Dermatology and Venereology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Correspondence
Armagan Kutlay, MD, Istanbul Universitesi, Istanbul Tıp Fakültesi Deri ve Zührevi Hastalıklar Anabilim Dalı, 34093 Fatih, Istanbul, Turkey.
Email: [email protected]
Search for more papers by this author Nesimi Buyukbabani,
Nesimi Buyukbabani
Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Search for more papers by this author
Can Baykal,
Can Baykal
Department of Dermatology and Venereology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Search for more papers by this author Armagan Kutlay,
Corresponding Author
Armagan Kutlay
Department of Dermatology and Venereology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Correspondence
Armagan Kutlay, MD, Istanbul Universitesi, Istanbul Tıp Fakültesi Deri ve Zührevi Hastalıklar Anabilim Dalı, 34093 Fatih, Istanbul, Turkey.
Email: [email protected]
Search for more papers by this author Nesimi Buyukbabani,
Nesimi Buyukbabani
Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Search for more papers by this author
First published: 12 April 2019
No abstract is available for this article.
CONFLICT OF INTEREST
None declared.
REFERENCES
- Berger, G. K., McBride, A., Lawson, S., Royball, K., Yun, S., Gee, K., … Anwer, F. (2017). Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review. Critical Reviews in Oncology/Hematology, 109, 42–50.
- Dennie, T. W., & Kolesar, J. M. (2009). Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clinical Therapeutics, 31, 2290–2311.
- Fecher, L. A. (2013). Systemic therapy for inoperable and metastatic basal cell cancer. Current Treatment Options in Oncology, 14, 237–248.
- Fujimura, T., Kakizaki, A., Kambayashi, Y., & Aiba, S. (2012). Basal cell carcinoma with spontaneous regression: A case report and immunohistochemical study. Case Reports in Dermatology, 4, 125–132.
- Ganti, A. K., & Kessinger, A. (2011). Systemic therapy for disseminated basal cell carcinoma: An uncommon manifestation of a common cancer. Cancer Treatment Reviews, 37, 440–443.
- Moeholt, K., Aagaard, H., Pfeiffer, P., & Hansen, O. (1996). Platinum-based cytotoxic therapy in basal cell carcinoma a review of the literature. Acta Oncologica, 35, 677–682.
- Rahman, S. M., Bhat, W., Wiper, J. D., & Platt, A. J. (2014). Clinical and histological resolution of a basal cell carcinoma in a patient undergoing concurrent treatment of B-cell lymphoma with systemic R-CHOP. Journal of Plastic, Reconstructive & Aesthethic Surgery, 67, 223–225.
- Sekulic, A., Migden, M. R., Lewis, K., Hainsworth, J. D., Solomon, J. A., Yoo, S., … Hauschild, A. (2015). Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. Journal of American Academy of Dermatology, 72, 1021–1026.
